Ascidian Therapeutics CEO Michael Ehlers is leaving the venture investor that serves as his home base and will join MPM ...
Sum­mit Ther­a­peu­tics and its Chi­nese part­ner Ake­so have a few com­peti­tors now.
GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...
The FDA has cleared PTC Ther­a­peu­tics’ gene ther­a­py for AADC de­fi­cien­cy, an ul­tra-rare dis­ease that im­pacts the ...
The GAO report highlights FDA's drug inspection program challenges, including 36% fewer inspections in 2023 compared to 2019 ...
The amylin field is heating up ahead of Novo Nordisk's much-anticipated CagriSema readout later this year. On Wednesday, ...
Johnson & Johnson is suing the federal government over HRSA's rejection of its proposed 340B drug discount model for Xarelto ...
Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in ...
Forward Health, a San Francisco-based primary care startup offering $150 monthly subscription services through ...
TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...
Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its spinouts Apriori ...
A lot of Amgen's future rides on its experimental obesity medicine MariTide. At least in the minds of investors. Ahead of the ...